Glycomine, Inc., A Biotechnology Company Focused On Developing New Therapies For Orphan Diseases, Announced That The Company Has Received Us Food And Drug Administration (Fda) Clearance Of An Investigational New Drug (Ind) Application For Glm101 For The Treatment Of Pmm2-Cdg And Has Initiated Dosing Healthy Volunteers In A Phase 1 Clinical Study. Glm101 Is A Mannose-1-Phosphate Replacement Therapy In Development To Treat Phosphomannomutase 2-Congenital Disorder Of Glycosylation (Pmm2-Cdg), Previously Known As Cdg Type Ia. Pmm2-Cdg Is The Most Prevalent Congenital Disease Of Glycosylation But Has No Fda-Approved Treatments.
